Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12055
Title: Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.
Authors: Rowe, Christopher C;Bourgeat, Pierrick;Ellis, Kathryn A;Brown, Belinda;Lim, Yen Ying;Mulligan, Rachel S;Jones, Gareth;Maruff, Paul;Woodward, Michael M;Price, Roger;Robins, Peter;Tochon-Danguy, Henri;O'Keefe, Graeme J;Pike, Kerryn E;Yates, Paul;Szoeke, Cassandra;Salvado, Olivier;Macaulay, S Lance;O'Meara, Timothy;Head, Richard;Cobiac, Lynne;Savage, Greg;Martins, Ralph N;Masters, Colin L;Ames, David;Villemagne, Victor L
Affiliation: Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia.
Issue Date: 1-Dec-2013
Citation: Annals of Neurology; 74(6): 905-13
Abstract: Biomarkers for Alzheimer disease (AD) can detect the disease pathology in asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive prognosis remains uncertain. We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals.A total of 183 healthy individuals (age = 72.0 ± 7.26 years) and 87 participants with MCI (age = 73.7 ± 8.27) in the Australian Imaging, Biomarkers, and Lifestyle study of ageing were studied. Clinical reclassification was performed after 3 years, blind to biomarker findings. β-Amyloid imaging was considered positive if the (11) C-Pittsburgh compound B cortical to reference ratio was ≥1.5.Thirteen percent of healthy persons progressed (15 to MCI, 8 to dementia), and 59% of the MCI cohort progressed to probable AD. Multivariate analysis showed β-amyloid imaging as the single variable most strongly associated with progression. Of combinations, subtle memory impairment (Z score = -0.5 to -1.5) with a positive amyloid scan was most strongly associated with progression in healthy individuals (odds ratio [OR] = 16, 95% confidence interval [CI] = 3.7-68; positive predictive value [PPV] = 50%, 95% CI = 19-81; negative predictive value [NPV] = 94%, 95% CI = 88-98). Almost all amnestic MCI subjects (Z score ≤ -1.5) with a positive amyloid scan developed AD (OR = ∞; PPV = 86%, 95% CI = 72-95; NPV = 100%, 95% CI = 80-100). Hippocampal atrophy and ε4 status did not add further predictive value.Subtle memory impairment with a positive β-amyloid scan identifies healthy individuals at high risk for MCI or AD. Clearly amnestic patients with a positive amyloid scan have prodromal AD and a poor prognosis for dementia within 3 years.
Internal ID Number: 24448836
URI: http://ahro.austin.org.au/austinjspui/handle/1/12055
DOI: 10.1002/ana.24040
URL: http://www.ncbi.nlm.nih.gov/pubmed/24448836
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Aging.pathology.physiology
Alzheimer Disease.diagnosis.genetics.pathology
Amyloid beta-Peptides.metabolism
Apolipoproteins E.genetics
Atrophy.pathology
Australia.epidemiology
Biological Markers
Female
Hippocampus.metabolism.pathology.physiopathology
Humans
Life Style
Male
Memory Disorders.diagnosis.pathology.physiopathology
Middle Aged
Mild Cognitive Impairment.diagnosis.genetics.pathology
Predictive Value of Tests
Single-Blind Method
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.